
Adagene and Third Arc Bio collaborate on masked CD3 T cell engagers
Under a new agreement, Third Arc Bio will utilise Adagene’s SAFEbody technology platform to generate masked CD3 T cell engagers against unique tumour associated antigens. In return, Third Arc Bio will receive rights to research, develop and commercialise two candidate molecules worldwide. Adagene will receive an upfront payment of $5… Read More
